Literature DB >> 29346673

Commentary on "The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis".

Philip McGuire1,2, Amir Englund1,2, Sagnik Bhattacharyya1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29346673      PMCID： PMC5768041          DOI： 10.1093/schbul/sbx124

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  11 in total

1.  Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia.

Authors:  F F Peres; M C Diana; M A Suiama; V Justi; V Almeida; R A Bressan; A W Zuardi; J E Hallak; J A Crippa; V C Abilio
Journal:  Schizophr Res       Date:  2016-02-05       Impact factor: 4.939

2.  Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

Authors:  Arsime Demjaha; Alice Egerton; Robin M Murray; Shitij Kapur; Oliver D Howes; James M Stone; Philip K McGuire
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

Review 3.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

4.  Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk.

Authors:  Paolo Fusar-Poli; Ilaria Bonoldi; Alison R Yung; Stefan Borgwardt; Matthew J Kempton; Lucia Valmaggia; Francesco Barale; Edgardo Caverzasi; Philip McGuire
Journal:  Arch Gen Psychiatry       Date:  2012-03

Review 5.  Can we make cannabis safer?

Authors:  Amir Englund; Tom P Freeman; Robin M Murray; Philip McGuire
Journal:  Lancet Psychiatry       Date:  2017-03-02       Impact factor: 27.083

6.  Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Authors:  Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

7.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222

8.  Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study.

Authors:  Rashmi Patel; Robin Wilson; Richard Jackson; Michael Ball; Hitesh Shetty; Matthew Broadbent; Robert Stewart; Philip McGuire; Sagnik Bhattacharyya
Journal:  BMJ Open       Date:  2016-03-03       Impact factor: 2.692

9.  Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.

Authors:  P Seeman
Journal:  Transl Psychiatry       Date:  2016-10-18       Impact factor: 6.222

10.  Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.

Authors:  Tabea Schoeler; Natalia Petros; Marta Di Forti; Ewa Klamerus; Enrico Foglia; Olesya Ajnakina; Charlotte Gayer-Anderson; Marco Colizzi; Diego Quattrone; Irena Behlke; Sachin Shetty; Philip McGuire; Anthony S David; Robin Murray; Sagnik Bhattacharyya
Journal:  Lancet Psychiatry       Date:  2016-08-23       Impact factor: 27.083
View more
  1 in total

1.  Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis.

Authors:  Cathy Davies; Joaquim Radua; Andrea Cipriani; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli
Journal:  Front Psychiatry       Date:  2018-06-12       Impact factor: 4.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.